News

cellvie Inc., a leader in Therapeutic Mitochondria Transplantation (TMT) an approach developed at Harvard Medical School, closes a $5.5 Million financing to get Series A-ready by the end of 2023.

$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital.

Berlin/Ulm, Germany – MoglingBio, a privately held biotech company, announces today that it has successfully completed its first seed investment round. Sole investor is venture capital firm Kizoo Technology Capital, a rejuvenation biotech investor focused on startups reversing age-related damage on a cellular and molecular level.

MoglingBio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by increased activity of the protein CDC42. This loss of structure leads to decreased production and quality of blood and immune cells. It can cause leukemia, various blood diseases, and severely weaken the immune system. Normalizing CDC42 activity can restore structure, order and functionality in those aged stem cells. Treated cells can perform their tasks again in a juvenile way, and thereby contribute to both, the rejuvenation of stem cells and the immune system.

The Inaugural Rejuvenation Startup Summit 2022, brought to you by the Forever Healthy Foundation, took place with over 400 participants from over 30 countries in October.

It is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry. The Summit brings together startups, members of the longevity venture capital / investor ecosystem, and researchers interested in founding or joining a startup – all aiming to create therapies to vastly extend the healthy human lifespan.

We started to publish videos with a first set of selected speakers on the 2022 summit

The Inaugural Rejuvenation Startup Summit 2022 took place with over 400 participants from over 30 countries. Thank you to all participant and your fantastic feedback – and: Thank you to all brilliant speakers and panelists to make this such a special event. Listening to the presentations of more than 30 longevity biotech start-ups, it is clear that there is an exciting future ahead!

We will be back in the years to come!

The Forever Healthy Foundation announces the public launch of the Risk-Benefit Analysis of Centrophenoxine for Health and Longevity, a structured review of the published evidence. It is the sixth publication of Forever Healthy’s “Rejuvenation Now” initiative, following the “Risk & Benefit Analysis of Phospholipid Therapy”.

For this risk and benefit analysis, the team at Forever Healthy screened over 1400 scientific papers and performed an in-depth analysis of more than 150 clinical trials to determine the usefulness and optimal application.

Forever Healthy’s “Rejuvenation Now” initiative seeks to continuously identify potential rejuvenation therapies and systematically evaluates them on risks, benefits, and therapeutic protocols to create transparency regarding the current state of said therapies.

The Forever Healthy Foundation is pleased to announce the world’s first Rejuvenation Startup Summit will be held October 14-15, 2022 in Berlin.

The Rejuvenation Startup Summit is a vibrant networking event for rejuvenation startups, longevity investors, and translational researchers, and aims to accelerate the development of the rejuvenation biotech industry.

Startups will be able to connect with investors in the longevity space, present their approach, and get them interested in their work. Investors can meet the most promising rejuvenation startups from all over the world and get in touch with them straight away. Researchers with a startup itch can learn how to successfully break out of the lab and found or join a rejuvenation startup.

The summit brings together all those working on therapies that aim to vastly extend the healthy human lifespan. In addition to an exciting range of keynotes speeches, presentations, and panels, the summit features an all-day startup forum for easy networking. Starting midday on Friday and finishing off on Saturday night with a big party, it offers ample opportunity to connect, learn and network with the most relevant players in the field.

The Rejuvenation Startup Summit is not only open to startups, investors, and translational scientists – all interested members of the broader longevity movement, scientists from related fields, aspiring students, and the general media are also welcome.

Learn more at: https://forever-healthy.org/summit

Greenville, SC, U.S. – Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, today announced the closing of a $10 million funding round led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies. Other investors in the round include Starbloom Capital and SC Launch. Elastrin Therapeutics was founded in 2018 as a spin-out from Clemson University, where the technology was first developed over a 20-year period.

San Francisco, CA, U.S. – Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing. The oversubscribed round was led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies, and Starbloom Capital with participation from Tubus LLC. The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic.

Today, enzymes are applied therapeutically in only a handful of applications, including for wrinkle treatment (Botox), cancer (Asparaginase), and cystic fibrosis (DNase). Revel Pharmaceuticals is reimagining how enzymes can be used as therapeutics by developing repair based approaches to aging and disease.

London, UK ­– Kizoo portfolio company Biotech LIfT BioSciences today announced its largest financing round to date with a further £5million investment into the company in its mission to develop the first curative and affordable cell therapy for all solid tumours. The round was led by new investor Starbloom Capital with additional participation by Jonathan Milner, a leading biotech ‘super-angel’ investor and earlier stage investor in LIfT, Kizoo Technology Ventures, a leading early-stage investor in breakthrough rejuvenation technologies and Downing Ventures, a leading London-based investor.

Karlsruhe, Germany and Novato, CA, USA

The Forever Healthy Foundation and the Buck Institute for Research on Aging today announced a new partnership to advance early-stage discoveries at the Institute that show promise to reverse physiologic aging in humans. The focus will be on cutting-edge research aimed at the repair of age-related damage at the cellular and molecular level, a hallmark of the aging process. Forever Healthy will commit up to $1 million per year for five years to drive this innovation. The funding aims to advance early-stage research with high translational potential in order to speed up the transition from lab to product.